Interactions between the renin-angiotensin system and dyslipidemia: Relevance in atherogenesis and therapy of coronary heart disease

Indian Heart Journal

Volumn 53, Issue 4, 2001, Pages 511-518

  Singh, B K ^a   Mehta, J L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLCHOLINE; ALPHA TOCOPHEROL; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CAPTOPRIL; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMBUSARTAN; ENALAPRIL; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; RENIN; SIMVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MODULATION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; RABBITS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035157767     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Aviram M. Modified forms of low-density lipoprotein and atherosclerosis. Atherosclerosis 1993; 98: 1-9
2. Keidar A, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular biosynthesis. Atherosclerosis 1999; 146: 249-257
3. Nazzaro P, Manzari M, Merlo M, Triggioni R, Scararo A, Ciancio L, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 719-725
4. Keidar S, Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63: 1-11
5. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996; 16: 97-105
6. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999; 84: 1043-1049
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430
8. Griendling KK, Minieri CA, Ollerenshaw JD, Alezander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
9. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033
10. Freinman PC, Mitchell GG, Heisted DD, Armstrong ML, Harrison DG. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986; 58: 783-789
11. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992
12. 1-receptor and of eicosanoids. J Cardiovasc Pharmacol Ther 2000; 5: 59-68
13. Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-2116
14. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478
15. Diet F, Prat RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767
16. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-1593
17. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carer RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction). Circulation 1996; 94: 258-265
18. Mitan H, Bandoh T, Kimura, M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol 1996; 271: H1065-H1071
19. 1 receptor over-expression in hypercholesterolaemia. And Med 2000; 32: 386-389
20. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378
21. Nickenig G, Sachinidis A, Seewald S, Bohm M, Vetter H. Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens 1997; 15 (Suppl): S27-S30
22. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102: 1970-1976
23. 1 receptor gene expression and cell proliferation in vascular smooth muscle cells. Kidney Blood Press Res 1999; 21: 392-393
24. 1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134
25. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyasaki M. Induction of chymase that forms angiontensin II in the monkey atherosclerotic aorta. FEBS Lett 1997; 412: 86-90
26. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828
27. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-587
28. Jacobsson LS, Persson K, Aberg G, Anderson RG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994; 24: 670-677
29. Chen H, Li D, Sawamura T, Inoue K, Mehta JL. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000; 276: 1100-1104
30. Bavry AA, Li D, Zander DS, Phillips MI, Mehta JL. Inhibition of arterial thrombogenesis by quinapril, but not losartan. J Cardiovasc Pharmacol Ther 2000; 5: 121-127
31. Conti CR, Mehta JL. Acute myocardial ischemia: role of atherosclerosis, thrombosis, platelet activation, coronary vasospasm. and altered arachidonic acid metabolism. Circulation 1987; 75: V84-V95
32. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-1612
33. Becker RH, Wiemer C, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18: S110-S115
34. Farhy RD, Carretero OA, Ho KL, Scicli AC. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993; 72: 1202-1210
35. Mehta JL, Li DY. Identification and autoregulation of receptor for Ox-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 1998; 248: 511-514
36. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidined low-density lipoprotein (LOX-1 ) in cultured human coronary artery endothelial cells by angiotensin II type-1 receptor activation. Circ Res 1999; 84: 1043-1049
37. Bickel PE, Freeman MW, Rabbit aortic smooth muscle cells express inducible macrophage scavenger receptor messenger RNA that is absent from endothelial cells. J Clin Invest 1992; 90: 1450-1457
38. Kume N, Aral H, Kawai C, Kita T. Receptors for modified low density lipoproteins on human endothelial cells: different recognition for acetylated low-density lipoprotein and oxidized low-density lipoprotein. Biochim Biophys Acta 1991; 1091: 63-67
39. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T A, et al. Inducible expression of receptor-1 leclin-like oxidized low density lipoprotein, in vascular endothelial cells. Circ Res 1998; 83: 322-527
40. Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998; 83: 328-333
41. Li DY, Yang BC, Mehta JL. Ox-LDL induces apoptosis in cultured human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol 1998; 275: H568-H576
42. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000; 20: 1116-1122
43. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889-2895
44. 1 receptor and PKC activation. Am J Physiol 1999; 276: H786-H792
45. Mehta JL, Li D. Facultative interaction between angiotensin II and oxidized LDL in cultured human coronary artery endothelial cells. J Ren Ang Ald Syst 2001; 2: D70-S76
46. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
47. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Wilson PW. Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999; 159: 2206-2212
48. Sung BH, Izzo JI, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997; 10: 592-599
49. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 719-725
50. Steinberg D, Witztum JL. Lipoproleins and atherogenesis. JAMA 1990; 264: 3047-3052
51. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18: S110-S115
52. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587
53. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-1 converting enzyme insertion/ deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the Lipoprotein and Coronary Atherosclerosis Study. J Am Coll Cardiol 2000; 35: 89-95
54. Cashin-Hemphill L, Dinsmore RE, Chan RC, Williams SN, Hombang G, Haver HF, et al. for the QUIET investigators. LDL cholesterol and angiographic progression in the QUIET trial. J Am Coll Cardiol 1997; 29: 85A
55. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACF inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058-1063
56. Pitt B, Pepine C, O'Neill B, Haber H, Pressler M, Mancini GBJ, for the TREND investigators. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low-density lipoprotein cholesterol. J Am Coll Cardiol 1997; 29: 70A
57. Yusuf S, Pepine CH, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178
58. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown FJ Jr, Cuddy TF, el al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677
59. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069
60. Rutherford JU, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90: 1731-1738
61. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
62. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925
63. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444
64. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996; 27: 1048-1052